TPM3 and non-small cell lung carcinoma: It indicates that TRK inhibitor is more effective than anti-PD-1 inhibitor monotherapy for patients with NTRK fusion-positive NSCLC in spite of higher TMB and positive PD-L1 expression simultaneously.